Sobi enters the Dow Jones Sustainability Indices (DJSI)
We are proud to announce that for the first time, Sobi has qualified as a constituent of the Dow Jones Sustainability Indices (DJSI). Sobi joins the DJSI Europe, and is one of eight companies within the industry grouping Pharmaceuticals, Biotechnology & Life Sciences.
In total, 153 companies across all industries were included in the DJSI Europe in 2022. Sobi was one of 20 companies added to the index.
"Sobi has reached another milestone on our sustainability journey. This is a recognition of Sobi’s high ambitions and acceleration within sustainability and was made possible by collaboration between many functions”, says Thomas Kudsk Larsen, Head of Communications and Investor Relations. “Management is fully committed to continuing to support our sustainability efforts to ensure continued progress in this area for Sobi.”
The DJSI is powered by the S&P Global Corporate Sustainability Assessment (CSA). The S&P CSA evaluates all topics that contribute to a company’s sustainability performance. The best performers in each of the 61 industries included become members of one or several of the DJSI indices. Sobi has been taking part in this assessment since 2020 and has now made the progress needed to become part of the Dow Jones Sustainability Indices (DJSI).
We provide access to innovative treatments that transform life for people.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present current and past media releases, images and videos.
- About
- Therapeutic areas
- Medicines
- Stories
- Sustainability
- Careers
- Investors
- Media
- English
- Swedish